TALLC is a new Montreal-based pharmaceutical company formed to exploit the value of TA-A001 and a follow-on pipeline of immunomodulatory drug candidates as treatments for acute and chronic inflammation.
Focussed initially on highly painful front of eye ophthalmic indications, TALLC will go on to demonstrate the benefits of TA-A001, TA-A002 (mixed CB1/2 receptor agonist) and TA-A003 (endocannabinoid augmenting enzyme inhibitor) in other areas of high unmet need including glaucoma and macula degeneration. Delivery of TALLC drug candidates topically, by injection or by inhalation, is enabled by SmartCelle micelles.
GB2561009 covers the chemical composition of SmartCelle polymers, their method of manufacture and their ability to form 20nm-30nm stable drug-loaded dynamic micelles in aqueous solution. SmartCelle formulations comprising a number of anti-inflammatory drugs are presented.
“This first SmartCelle patent is an invaluable addition to our growing patent portfolio and we expect it to issue in N. America shortly” said Damon Smith CEO of TALLC.
“SmartCelle is an enabling technology for delivery of highly insoluble molecules and designed to provide improved corneal and back-of-eye access for TA-A001 and our range drug candidates after topical administration”. Dr. Smith added “Chronic inflammation underlies many of the painful and sight-threatening conditions seen in increasing numbers by ophthalmologists today.
We believe that our full CB2 agonist TA-A001, enabled by SmartCelle technology, can improve the lives of patients suffering these debilitating diseases”.
Read the original article on Life Science Newswire.
